Thrombospondin enhances RANKL-dependent osteoclastogenesis and facilitates lung cancer bone metastasis

Jemal, 2007, Cancer statistics, 2007, CA Cancer J. Clin., 57, 43, 10.3322/canjclin.57.1.43 Huang, 2017, A review on the effects of current chemotherapy drugs and natural agents in treating non-small cell lung cancer, BioMedicine, 7, 23, 10.1051/bmdcn/2017070423 Tu, 2018, Cigarette smoke enhances oncogene addiction to c-MET and desensitizes EGFR-expressing non-small cell lung cancer to EGFR TKIs, Mol. Oncol., 12, 705, 10.1002/1878-0261.12193 Hu, 2017, Association of HMGB1 gene polymorphisms with lung cancer susceptibility and clinical aspects, Int. J. Med. Sci., 14, 1197, 10.7150/ijms.20933 Hu, 2017, Periostin promotes epithelial-mesenchymal transition via the MAPK/miR-381 axis in lung cancer, Oncotarget, 8, 62248, 10.18632/oncotarget.19273 Coniglio, 2018, Role of tumor-derived chemokines in osteolytic bone metastasis, Front. Endocrinol., 9, 313, 10.3389/fendo.2018.00313 Chen, 2014, The CCN family proteins: modulators of bone development and novel targets in bone-associated tumors, BioMed Res. Int., 2014 Tang, 2008, Involvement of matrix metalloproteinase-9 in stromal cell-derived factor-1/CXCR4 pathway of lung cancer metastasis, Carcinogenesis, 29, 35, 10.1093/carcin/bgm220 Chen, 2011, RANKL increases migration of human lung cancer cells through intercellular adhesion molecule-1 up-regulation, J. Cell. Biochem., 112, 933, 10.1002/jcb.23009 Stopeck, 2010, Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study, J. Clin. Oncol., 28, 5132, 10.1200/JCO.2010.29.7101 Fong, 2008, Osteoblast-derived TGF-beta1 stimulates IL-8 release through AP-1 and NF-kappaB in human cancer cells, J. Bone Mineral Res., 23, 961, 10.1359/jbmr.080206 Tawara, 2011, Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies, Cancer Manage. Rese., 3, 177 Roberts, 2008, Thrombospondins: from structure to therapeutics, Cell. Mol. Life Sci.: CMLS, 65, 669, 10.1007/s00018-007-7483-2 Armstrong, 2003, Thrombospondins 1 and 2 function as inhibitors of angiogenesis, Matrix Biol., 22, 63, 10.1016/S0945-053X(03)00005-2 Hankenson, 2002, The secreted protein thrombospondin 2 is an autocrine inhibitor of marrow stromal cell proliferation, J. Bone Mineral Res., 17, 415, 10.1359/jbmr.2002.17.3.415 Resovi, 2014, Current understanding of the thrombospondin-1 interactome, Matrix Biol., 37, 83, 10.1016/j.matbio.2014.01.012 Kodama, 2001, Thrombospondin-1 and -2 messenger RNA expression in invasive cervical cancer: correlation with angiogenesis and prognosis, Clin. Cancer Res., 7, 2826 Santin, 2004, Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy, Int. J. Cancer, 112, 14, 10.1002/ijc.20408 Sun, 2014, Down regulation of Thrombospondin2 predicts poor prognosis in patients with gastric cancer, Mol. Cancer, 13, 225, 10.1186/1476-4598-13-225 Hsu, 2014, Secretome profiling of primary cells reveals that THBS2 is a salivary biomarker of oral cavity squamous cell carcinoma, J. Proteome Res., 13, 4796, 10.1021/pr500038k Chen, 2017, Thrombospondin-2 promotes prostate cancer bone metastasis by the up-regulation of matrix metalloproteinase-2 through down-regulating miR-376c expression, J. Hematol. Oncol., 10, 33, 10.1186/s13045-017-0390-6 Liu, 2018, Thrombospondin 2 promotes tumor metastasis by inducing matrix metalloproteinase-13 production in lung cancer cells, Biochem. Pharmacol., 155, 537, 10.1016/j.bcp.2018.07.024 Wu, 2012, Endothelin-1 promotes MMP-13 production and migration in human chondrosarcoma cells through FAK/PI3K/Akt/mTOR pathways, J. Cell. Physiol., 227, 3016, 10.1002/jcp.23043 Hou, 2009, Bone morphogenetic protein-2 enhances the motility of chondrosarcoma cells via activation of matrix metalloproteinase-13, Bone, 44, 233, 10.1016/j.bone.2008.09.021 Lee, 2019, Plumbagin suppresses endothelial progenitor cell-related angiogenesis in vitro and in vivo, J. Funct. Foods, 52, 537, 10.1016/j.jff.2018.11.040 Chang, 2018, Osteoblast-secreted WISP-1 promotes adherence of prostate cancer cells to bone via the VCAM-1/integrin alpha4beta1 system, Cancer Lett., 426, 47, 10.1016/j.canlet.2018.03.050 Tang, 2008, Bone-derived SDF-1 stimulates IL-6 release via CXCR4, ERK and NF-kappaB pathways and promotes osteoclastogenesis in human oral cancer cells, Carcinogenesis, 29, 1483, 10.1093/carcin/bgn045 Tsai, 2008, Paeonol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38 and NF-kappaB pathway, Eur. J. Pharmacol., 588, 124, 10.1016/j.ejphar.2008.04.024 Lien, 2018, Chemokine CCL4 induces vascular endothelial growth factor C expression and lymphangiogenesis by miR-195-3p in oral squamous cell carcinoma, Front. Immunol., 9, 412, 10.3389/fimmu.2018.00412 Chen, 2013, CCN3 promotes prostate cancer bone metastasis by modulating the tumor-bone microenvironment through RANKL-dependent pathway, Carcinogenesis, 34, 1669, 10.1093/carcin/bgt103 Kim, 2015, Loss of RUNX3 expression promotes cancer-associated bone destruction by regulating CCL5, CCL19 and CXCL11 in non-small cell lung cancer, J. Pathol., 237, 520, 10.1002/path.4597 Taverna, 2017, Amphiregulin contained in NSCLC-exosomes induces osteoclast differentiation through the activation of EGFR pathway, Scientific Rep., 7, 3170, 10.1038/s41598-017-03460-y Park, 2017, Current understanding of RANK signaling in osteoclast differentiation and maturation, Mol. Cells, 40, 706 Gennari, 2017, MicroRNAs in bone diseases, Osteoporos Int., 28, 1191, 10.1007/s00198-016-3847-5 Battafarano, 2018, Cellular and molecular mediators of bone metastatic lesions, Int. J. Mol. Sci., 19, 10.3390/ijms19061709 Tsoukalas, 2018, Advanced small cell lung cancer (SCLC): new challenges and new expectations, Ann. Transl. Med., 6, 145, 10.21037/atm.2018.03.31 Pabani, 2018, Current landscape of immunotherapy for the treatment of metastatic non-small-cell lung cancer, Curr. Oncol., 25, S94, 10.3747/co.25.3750 Schmid-Alliana, 2018, Understanding the progression of bone metastases to identify novel therapeutic targets, Int. J. Mol. Sci., 19, 10.3390/ijms19010148 Kunstfeld, 2014, Thrombospondin-2 overexpression in the skin of transgenic mice reduces the susceptibility to chemically induced multistep skin carcinogenesis, J. Dermatol. Sci., 74, 106, 10.1016/j.jdermsci.2014.01.002 Matos, 2013, Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia, Exp. Mol. Pathol., 94, 438, 10.1016/j.yexmp.2013.02.002 Mundy, 2002, Metastasis to bone: causes, consequences and therapeutic opportunities, Nature reviews, Cancer, 2, 584 Vicent, 2015, Bone metastases in lung cancer. Potential novel approaches to therapy, Am. J. Respiratory Critical Care Med., 192, 799, 10.1164/rccm.201503-0440SO Liu, 2015, Receptor activator of nuclear factor-kappaB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review), Mol. Med. Rep., 11, 3212, 10.3892/mmr.2015.3152 Weichhaus, 2015, Osteoprotegerin in breast cancer: beyond bone remodeling, Mol. Cancer, 14, 117, 10.1186/s12943-015-0390-5 Kanwal, 2017, MicroRNAs in prostate cancer: functional role as biomarkers, Cancer Lett., 407, 9, 10.1016/j.canlet.2017.08.011 Jiang, 2017, TGFbeta/SMAD/microRNA-486-3p signaling axis mediates keratin 17 expression and keratinocyte hyperproliferation in psoriasis, J. Investigative Dermatol., 137, 2177, 10.1016/j.jid.2017.06.005 Ye, 2016, MiR-486-3p targeting ECM1 represses cell proliferation and metastasis in cervical cancer, Biomed. Pharmacotherapy, 80, 109, 10.1016/j.biopha.2016.02.019